New pill aims to plug protein leak in kidney patients

NCT ID NCT07614477

Recruiting now Disease control Sponsor: Everest Medicines (China) Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease (FSGS, MCD, or IgA nephropathy) that cause protein to leak into urine. Participants take the drug twice daily for a year. The main goal is to see if it safely reduces protein levels and helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EVER001 (oral capsule, 200 mg twice daily)
What this could lead to: If successful, EVER001 could offer a new treatment option for people with certain kidney diseases, potentially reducing protein leakage and preserving kidney function.
What could go wrong: This is an early-phase study with only 45 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve kidney health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal segmental glomerulosclerosis IgA glomerulonephritis lipoid nephrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) IGA NEPHROPATHY (IGAN) MINIMAL CHANGE DISEASE (MCD)

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China
Tianjin Medical University General Hospital
RECRUITING

Tianjin, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.